about
Improved Stability and Smart-Material Functionality Realized in an Energetic CocrystalCo-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients.Theophylline-gentisic acid (1/1).On the origin of surface imposed anisotropic growth of salicylic and acetylsalicylic acids crystals during droplet evaporation.Nonlinear optical imaging for sensitive detection of crystals in bulk amorphous powders.Organized polysaccharide fibers as stable drug carriers.Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug.Cyanoximes as effective and selective co-crystallizing agents.Benefits of cocrystallisation in pharmaceutical materials science: an update.Ionic liquids in drug delivery.Critical gases for critical issues: CO2 technologies for oral drug delivery.Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics.New forms of old drugs: improving without changing.Pharmaceutical cocrystals: along the path to improved medicines.Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.Towards medicinal mechanochemistry: evolution of milling from pharmaceutical solid form screening to the synthesis of active pharmaceutical ingredients (APIs).Design of co-crystals/salts of some Nitrogenous bases and some derivatives of thiophene carboxylic acids through a combination of hydrogen and halogen bonds.Predicting the Solubility of Pharmaceutical Cocrystals in Solvent/Anti-Solvent Mixtures.Do carboximide-carboxylic acid combinations form co-crystals? The role of hydroxyl substitution on the formation of co-crystals and eutectics.Crystal structure of ethyl 4-[(E)-(4-hy-droxy-3-meth-oxy-benzyl-idene)amino]-benzoate: a p-hy-droxy Schiff baseDrug solubility: importance and enhancement techniques.Continuous engineering of nano-cocrystals for medical and energetic applications.Mixing of immiscible polymers using nanoporous coordination templates.2-[(4-Hydroxy-phen-yl)diazen-yl]benzoic acid-N,N'-bis-(4-pyridylmeth-yl)oxamide (2/1).4,4'-Bipyridine-pyroglutamic acid (1/2).N-(4,6-Dimethyl-pyrimidin-2-yl)-4-(oxolan-2-ylamino)benzene-sulfonamidePharmaceutical Cocrystal of Piroxicam: Design, Formulation and Evaluation.Investigation of the Formation Process of Two Piracetam Cocrystals during Grinding.Identification of a new co-crystal of salicylic acid and benzamide of pharmaceutical relevance.Stereoselectivity in the salt-cocrystal products formed by phenylglycinol or phenylglycine with their respective sodium or hydrochloride salts.Solvates of the antifungal drug griseofulvin: structural, thermochemical and conformational analysis.Eutectics as improved pharmaceutical materials: design, properties and characterization.Easy methods to study the smart energetic TNT/CL-20 co-crystal.Two isostructural explosive cocrystals with significantly different thermodynamic stabilities.Creation of ternary multicomponent crystals by exploitation of charge-transfer interactions.Formulation and physicochemical characterization of chitosan/acyclovir co-crystals.In vivo brain microdialysis as a formulation-screening tool for a poorly soluble centrally acting drug.A tale of two polymorphic pharmaceuticals: pyrithyldione and propyphenazone and their 1937 co-crystal patent.On the hydrates of codeine phosphate: the remarkable influence of hydrogen bonding on the crystal size.Preparation and Characterization of Cabamazepine Cocrystal in Polymer Solution.
P2860
Q29042596-91129AA6-0199-4DED-AF71-AF142A4BD83BQ33834542-8F2209AC-ECE1-467D-99D4-0486FA5285EBQ34266265-1850C39E-9A4D-4BFD-BBDF-E36B5D748534Q35097532-779C0E56-DFA5-4D19-B0D6-0F30C4D028E8Q36662432-65DCEB4A-5370-4888-A5D6-7BF4968926DEQ36982139-6A66D244-C3F6-4328-A9F5-4B3EFD23A2E0Q37032759-FB482A42-D5F5-4D56-A332-B5591A1B8564Q37357776-17B5FA59-9DB6-4B3C-806E-7DAB8D1C5EA0Q37805586-9ACF33B4-24D0-4700-9B23-595B4C77EF2DQ38116530-7DFB0092-B7E4-4F8D-8BCE-D3CD505610DCQ38183855-5F39BC98-907B-4EAD-B5E8-1CBE1C90C553Q38236638-405A90FE-68CA-4343-94A2-CD1F19BD5FB7Q38342804-ADD40242-3177-4C1B-88DB-CB013ABE4AD7Q38632654-BDDF72A0-4443-4A3D-8395-7B9A36F6A65BQ38865422-A6D40106-AE45-4996-9E55-FA204E1CEF8FQ38866596-2C915F85-87FC-4441-8CEC-EDD7758F96DFQ38912338-87D3E2B1-204B-42D9-ACE4-EB290E4AE2F8Q39778934-24CFDF42-99A1-421B-A5AD-1AF3F3D47C09Q40296879-2127F66B-57C2-4BB5-87D9-485E43553985Q41473537-9CF0FDC3-A977-437D-968E-D5EF63357183Q41885580-CFE1F305-C8B7-4E37-BA35-CD61A958F929Q41942242-E9F7D853-F296-4D91-B967-F7B18FC974E0Q42355811-97BAC7EB-5BFB-4359-BC55-2BF498A55B61Q42383500-E9722FD5-1470-4B9E-A315-BDB697587FBCQ42384891-F228E624-6921-4A45-85F2-ED0855B89E7CQ42385054-C204344D-31CD-4F98-A4D1-7C64F8CFC57AQ42658216-C61C4821-0AB9-42E4-8ED2-6027E05D5BE9Q42830904-2271749C-C1D3-49DD-9E53-49DA0589893DQ43206052-574DDE5F-2BF9-417E-B16F-A52B01DB8B15Q43630008-9F0E2F8F-3DF7-47BC-9CB5-A7D3AE0BF968Q43953806-D2FC53E2-BF3B-4A4A-BEA5-DAA57B8B5562Q44122680-F20F7704-FE75-45DB-91EC-4AB3200BED2CQ44413282-21DE543A-A97C-4FA1-856A-4772DEB1C2AAQ44703693-8288526C-E3ED-49F9-906A-00EEC5A38066Q46006404-1F774B63-0E7F-45BB-8D6C-F53D0E93E4FCQ46163854-EF9C3DAC-9169-4270-9DE1-86BEBB138A22Q46646546-7D8B27F5-CAED-47A3-B5AD-E9B89150B912Q46768022-EFFD9797-3EB9-4AC4-BE02-5928A46868F9Q47178195-0A86F9B9-8CDB-49E0-87EB-0B8A2F9B4D8BQ47294973-5CAD4D59-7C1E-443A-A00E-A99E99F4D098
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of cocrystals in pharmaceutical science.
@en
The role of cocrystals in pharmaceutical science.
@nl
type
label
The role of cocrystals in pharmaceutical science.
@en
The role of cocrystals in pharmaceutical science.
@nl
prefLabel
The role of cocrystals in pharmaceutical science.
@en
The role of cocrystals in pharmaceutical science.
@nl
P1433
P1476
The role of cocrystals in pharmaceutical science.
@en
P2093
P304
P356
10.1016/J.DRUDIS.2008.03.004
P577
2008-04-22T00:00:00Z